Stable crystal modifications of DOTAP chloride
The invention relates to enantiomerically pure DOTAP chloride and stable crystal modifications of (2R,S)-, (2S)- and (2R)-DOTAP chloride, to a process for the preparation of these modifications, and to the use thereof as constituent for the preparation of medicaments.
1. A pharmaceutical composition comprising enantiomerically pure (2R)-DOTAP chloride and a pharmaceutically acceptable carrier, with the proviso that the composition is substantially free of (2S)-DOTAP chloride.
2. A pharmaceutical composition according to claim 1 , further comprising one or more peptides, nucleotides, vaccines or cytostatic agents, or a mixture thereof.
3. A pharmaceutical composition according to claim 1 , further comprising one or more liposomes, lipoplexes, nanoparticles or microemulsions, or a mixture thereof.